[go: up one dir, main page]

PE11399A1 - COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA - Google Patents

COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA

Info

Publication number
PE11399A1
PE11399A1 PE1997000968A PE00096897A PE11399A1 PE 11399 A1 PE11399 A1 PE 11399A1 PE 1997000968 A PE1997000968 A PE 1997000968A PE 00096897 A PE00096897 A PE 00096897A PE 11399 A1 PE11399 A1 PE 11399A1
Authority
PE
Peru
Prior art keywords
patient
asthma
loratadine
combination
treatment
Prior art date
Application number
PE1997000968A
Other languages
Spanish (es)
Inventor
Alan G Harris
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE11399A1 publication Critical patent/PE11399A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO COMBINADO DEL ANTIHISTAMINICO ANTISEDANTE LORATADINA Y DE UN DESCONGESTIONANTE PARA LA MANUFACTURA DE UN MEDICAMENTO PARA MEJORAR LA FUNCION PULMONAR DE UN PACIENTE QUE PADECE ASMA INCLUYENDO LA ADMINISTRACION AL PACIENTE DE UN TRATAMIENTO HABITUAL PARA LA RINITIS; EN DONDE DICHO DESCONGESTIVO SE SELECCIONA DE FENILPROPANOLAMINA, EFEDRINA, FENILEFRINA, PSEUDOEFEDRINA O UNA COMBINACION DE LAS MISMAS. SE MUESTRA QUE EL USO DE ANTIHISTAMINICOS QUE ERA CONTRAINDICADO SI EL PACIENTE TENIA ASMA, TENDRIA UN EFECTO BENEFICIOSO EN EL PACIENTE ASMATICO, INDEPENDIENTE SI EL PACIENTE PADECE O NO PADECE RINITISIT REFERS TO THE COMBINED USE OF THE ANTI-HISTAMINE ANTISEDANT LORATADINE AND A DECONSTRUCTANT FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO IMPROVE THE LUNG FUNCTION OF A PATIENT WHO SUFFERS FROM ASTHMA INCLUDING ADMINISTRATION TO THE PATIENT OF A HABITUAL TREATMENT; WHERE SAID DECONGESTIVE IS SELECTED FROM PHENYL PROPANOLAMINE, EPHEDRINE, PHENYLEPHRINE, PSEUDOEFEDRINE OR A COMBINATION OF THE SAME. IT IS SHOWN THAT THE USE OF ANTIHISTAMINES THAT WAS CONTRAINDICATED IF THE PATIENT HAD ASTHMA, WOULD HAVE A BENEFICIAL EFFECT ON THE ASTHMATIC PATIENT, INDEPENDENT IF THE PATIENT SUFFERS OR DOESN'T HAVE RHINITIS

PE1997000968A 1996-10-31 1997-10-29 COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA PE11399A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31

Publications (1)

Publication Number Publication Date
PE11399A1 true PE11399A1 (en) 1999-02-09

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000968A PE11399A1 (en) 1996-10-31 1997-10-29 COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA

Country Status (21)

Country Link
EP (1) EP0941091A1 (en)
JP (1) JP2000505104A (en)
KR (1) KR20000052922A (en)
CN (1) CN1235545A (en)
AR (1) AR008908A1 (en)
AU (1) AU731756B2 (en)
BR (1) BR9712705A (en)
CA (1) CA2268546A1 (en)
CO (1) CO4910128A1 (en)
CZ (1) CZ150999A3 (en)
HU (1) HUP9904075A3 (en)
ID (1) ID23431A (en)
IL (1) IL129662A0 (en)
NO (1) NO992062L (en)
NZ (1) NZ335078A (en)
PE (1) PE11399A1 (en)
PL (1) PL333056A1 (en)
SK (1) SK54599A3 (en)
TR (1) TR199901003T2 (en)
WO (1) WO1998018470A1 (en)
ZA (1) ZA979731B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021556A1 (en) * 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IT1303671B1 (en) * 1998-07-28 2001-02-23 Nicox Sa SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM
WO2000015226A1 (en) * 1998-09-10 2000-03-23 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (en) * 1999-02-23 2005-08-01 주식회사유한양행 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
CN1161112C (en) * 1999-02-23 2004-08-11 株式会社柳韩洋行 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
JP5592042B2 (en) * 2000-04-14 2014-09-17 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド Single dose antihistamine / decongestant formulation for the treatment of rhinitis
WO2001089527A2 (en) * 2000-05-24 2001-11-29 Schering Corporation Pharmaceutical composition comprising loratadine and a nasal decongestant
MXPA03011705A (en) * 2001-06-20 2004-03-19 Schering Corp Antihistamines for the treatment of nasal congestion and nasal obstruction.
NZ588134A (en) 2005-06-17 2010-11-26 Aft Pharmaceuticals Ltd Novel pharmaceutical for use in a method for treatment of upper respiratory mucosal congestion
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
RU2454225C2 (en) * 2006-06-01 2012-06-27 Эм Эс Ди Консьюмер Кэар, Инк. Pharmaceutical dosage forms and compositions of colon absorbed phenylephrine
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
HUP9904075A2 (en) 2000-05-28
SK54599A3 (en) 2000-08-14
CZ150999A3 (en) 1999-10-13
NO992062D0 (en) 1999-04-29
PL333056A1 (en) 1999-11-08
AR008908A1 (en) 2000-02-23
ZA979731B (en) 1998-04-29
NO992062L (en) 1999-04-29
AU4995397A (en) 1998-05-22
BR9712705A (en) 1999-10-26
ID23431A (en) 2000-04-20
JP2000505104A (en) 2000-04-25
HUP9904075A3 (en) 2002-02-28
AU731756B2 (en) 2001-04-05
CA2268546A1 (en) 1998-05-07
NZ335078A (en) 2000-10-27
TR199901003T2 (en) 1999-07-21
EP0941091A1 (en) 1999-09-15
WO1998018470A1 (en) 1998-05-07
KR20000052922A (en) 2000-08-25
CO4910128A1 (en) 2000-04-24
CN1235545A (en) 1999-11-17
IL129662A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
PE11399A1 (en) COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA
ES2166111T3 (en) USE OF TIAGABINE FOR THE TREATMENT OF SLEEP DISORDERS.
BR0008276A (en) Combinations of formoterol and fluticasone propionate for asthma
DE60117615D1 (en) MEDICINAL COMBINATIONS (FOR EXAMPLE CHLOROPROMAZINE AND PENTAAMIDINE) FOR THE THERAPY OF NEOPLASTIC DISEASES
HUP9700603A1 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
DE69738000D1 (en) New pharmaceutical formulation containing budesonide
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
HUP0203556A2 (en) Pharmaceutical compositions containing oxcarbazepine and their use
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
ATE329608T1 (en) FORMULATIONS OF COPOLYMER 1 (GLATIRAMER ACETATE) FOR ORAL, NASAL AND PULMONARY ADMINISTRATION
AR016798A1 (en) USE OF A LACTOBACILLUS CEPA FOR THE PREPARATION OF A MEDICINAL PRODUCT
BRPI0108435B8 (en) formulation and use of low-dose entecavir
NO990522D0 (en) Use of <beta> -sheet mimetics as protease and kinase inhibitors of transcription factors
AR030829A1 (en) A FORMATION OF VACCINE, PROCEDURE FOR THE PRODUCTION OF THE SAME, USE OF SUCH PREPARATION AND A CASE FOR ADMINISTRATION VIA INTRANASAL
DE69932510D1 (en) VASKULARISIERUNGSINHIBITOREN
NO20004419D0 (en) New use
ATE291914T1 (en) MEDICINAL COMPOSITIONS CONTAINING ZOLEMTRIPT
DE60002885D1 (en) AQUEOUS FORMULATION FOR NASAL ADMINISTRATION
DE60214527D1 (en) USE OF FLUMAZENIL IN THE DEVELOPMENT OF A MEDICAMENT FOR THE TREATMENT OF ALCOHOL DEPENDENCE
AR023687A1 (en) A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
NO20013414L (en) New use of melagatran
DE60128100D1 (en) ANALGICAL DRUG
ATE271852T1 (en) IMPROVED INHALATION PREPARATIONS
HUP0204097A2 (en) Use of guanosine-3',5'monophosphate phosphodiesteraze-inhibitor for production of pharmaceutical compositions available for treatment of diabetic ulcers
HUP0202931A2 (en) A pharmaceutically effective composition and the device for its administration

Legal Events

Date Code Title Description
FC Refusal